Clinical trial • Phase I • Infectious Disease

Clinical trial in Human immunodeficiency virus (HIV) infection

Phase I trial for Human immunodeficiency virus (HIV) infection. 6 participants.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
Human immunodeficiency virus (HIV) infection
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
11-10-2023
First CTIS Authorization Date
09-02-2024

Trial design

Phase I trial across 1 site in Netherlands.

Target Sample Size
6
Trial Duration For Participant
483

Eligibility

Recruits 6 Vulnerable population not selected (isVulnerablePopulationSelected:false).

Vulnerable Population
Vulnerable population not selected (isVulnerablePopulationSelected:false)

Recruitment

Planned Sample Size
6
Recruitment Window Months
19

Geography

Total Number Of Sites
1
Total Number Of Participants
6

Netherlands

Earliest CTIS Part Ii Submission Date
05-02-2024
Latest Decision Or Authorization Date
09-02-2024
Processing Time Days
4
Number Of Sites
1
Number Of Participants
6

Sites

Site Name
Amsterdam UMC
Department Name
Internal Medicine
Contact Person Name
G.J. De Bree
Contact Person Email
g.j.debree@amsterdamumc.nl
Number Of Participants
6

Sponsor

Primary sponsor

Full Name
International AIDS Vaccine Initiative Inc.
Organisation Type
Laboratory/Research/Testing facility
Country Of Registered Address
United States

Related trials

Other published trials that may interest you.